Cutler Investment Counsel LLC Buys 872 Shares of Merck & Company, Inc....

Cutler Investment Counsel LLC Buys 872 Shares of Merck & Company, Inc. (MRK)

167
0
SHARE

Cutler Investment Counsel LLC increased its position in shares of Merck & Company, Inc. (NYSE:MRK) by 0.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 105,440 shares of the company’s stock after buying an additional 872 shares during the period. Merck & Company comprises 1.8% of Cutler Investment Counsel LLC’s holdings, making the stock its 27th largest position. Cutler Investment Counsel LLC’s holdings in Merck & Company were worth $6,581,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. HighPoint Advisor Group LLC boosted its stake in shares of Merck & Company by 4.6% in the third quarter. HighPoint Advisor Group LLC now owns 29,788 shares of the company’s stock worth $1,867,000 after buying an additional 1,300 shares during the period. ETRADE Capital Management LLC boosted its stake in shares of Merck & Company by 22.8% in the third quarter. ETRADE Capital Management LLC now owns 115,363 shares of the company’s stock worth $7,199,000 after buying an additional 21,442 shares during the period. D.A. Davidson & CO. boosted its stake in shares of Merck & Company by 16.8% in the third quarter. D.A. Davidson & CO. now owns 433,599 shares of the company’s stock worth $27,056,000 after buying an additional 62,265 shares during the period. Bainco International Investors boosted its stake in shares of Merck & Company by 3.9% in the third quarter. Bainco International Investors now owns 145,128 shares of the company’s stock worth $9,057,000 after buying an additional 5,500 shares during the period. Finally, Sheets Smith Wealth Management boosted its stake in shares of Merck & Company by 3.7% in the third quarter. Sheets Smith Wealth Management now owns 17,057 shares of the company’s stock worth $1,065,000 after buying an additional 609 shares during the period. 74.10% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)

Merck & Company, Inc. (NYSE:MRK) opened at 65.26 on Friday. Merck & Company, Inc. has a 12-month low of $49.63 and a 12-month high of $65.87. The company’s 50-day moving average is $62.21 and its 200 day moving average is $61.91. The stock has a market capitalization of $179.93 billion, a PE ratio of 31.99 and a beta of 0.79.

Merck & Company (NYSE:MRK) last released its quarterly earnings results on Thursday, February 2nd. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.00. Merck & Company had a return on equity of 24.08% and a net margin of 14.30%. The firm had revenue of $10.10 billion for the quarter, compared to analysts’ expectations of $10.22 billion. During the same quarter last year, the firm posted $0.93 EPS. The company’s revenue was down 1.0% compared to the same quarter last year. On average, analysts predict that Merck & Company, Inc. will post $3.81 EPS for the current year.

“[[title]]” was originally posted by [[site]] and is the property of of [[site]]. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international trademark & copyright laws. The correct version of this article can be read at [[permalink]].

A number of brokerages recently weighed in on MRK. BMO Capital Markets reduced their price target on shares of Merck & Company from $72.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday. Vetr raised shares of Merck & Company from a “sell” rating to a “hold” rating and set a $59.51 price target for the company in a research report on Wednesday, January 25th. Bryan, Garnier & Co began coverage on shares of Merck & Company in a research report on Friday, January 13th. They issued a “buy” rating for the company. Jefferies Group LLC reissued an “underperform” rating and issued a $48.00 price target on shares of Merck & Company in a research report on Thursday, January 12th. Finally, Piper Jaffray Companies raised shares of Merck & Company from a “neutral” rating to an “overweight” rating and set a $72.00 price target for the company in a research report on Thursday, January 12th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $66.91.

In other Merck & Company news, Director Wendell P. Weeks sold 5,000 shares of the firm’s stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $64.51, for a total value of $322,550.00. Following the sale, the director now owns 5,100 shares of the company’s stock, valued at approximately $329,001. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael J. Holston sold 91,959 shares of the firm’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $63.96, for a total value of $5,881,697.64. Following the completion of the sale, the executive vice president now directly owns 105,559 shares in the company, valued at approximately $6,751,553.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 106,959 shares of company stock worth $6,843,448. Insiders own 0.05% of the company’s stock.

About Merck & Company

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

SHARE
Dan specializes in matters of money management and personal finance and has been published on numerous financial, business, health and wellness and sports websites.

LEAVE A REPLY